Finder's Pick for
Beginners
Bristol-Myers Squibb Company is a drug manufacturers-general business based in the US. Bristol-Myers Squibb Company stocks (BMY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $77.69 – an increase of 7.04% over the previous week. Bristol-Myers Squibb Company employs 32,200 staff and has a trailing 12-month revenue of around $47 billion.
How to buy stocks in Bristol-Myers Squibb Company
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BMY – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Finder's Pick for
Global Trading
Finder's Pick for
Commodity Stocks
Finder's Pick for
Free Trades
What's in this guide?
- Can I buy shares in Bristol-Myers Squibb Company?
- Has coronavirus impacted Bristol-Myers Squibb Company shares?
- Bristol-Myers Squibb Company shares summary
- Compare share dealing platforms
- Is Bristol-Myers Squibb Company stock a buy or sell?
- Bristol-Myers Squibb Company performance over time
- Is Bristol-Myers Squibb Company suitable for ethical investing?
- Are Bristol-Myers Squibb Company shares over-valued?
- Bristol-Myers Squibb Company's financials
- How volatile are Bristol-Myers Squibb Company shares?
- Does Bristol-Myers Squibb Company pay a dividend?
- Have Bristol-Myers Squibb Company shares ever split?
- Other common questions
Bristol-Myers Squibb Company stock price (NYSE:BMY)
Use our graph to track the performance of BMY stocks over time.Bristol-Myers Squibb Company shares at a glance
Information last updated 2022-06-24.
| Latest market close | $78.96 |
|---|---|
| 52-week range | $52.37 - $79.00 |
| 50-day moving average | $76.00 |
| 200-day moving average | $66.44 |
| Wall St. target price | $80.62 |
| PE ratio | 27.9702 |
| Dividend yield | $2.06 (2.93%) |
| Earnings per share (TTM) | $2.82 |
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
1 - 6 of 6
Online stock trading
Is it a good time to buy Bristol-Myers Squibb Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Bristol-Myers Squibb Company price performance over time
Historical closes compared with the close of $78.96 from 2022-06-24
| 1 week (2022-06-17) | 7.04% |
|---|---|
| 1 month (2022-05-25) | 2.23% |
| 3 months (2022-03-25) | 7.75% |
| 6 months (2021-12-23) | 27.25% |
| 1 year (2021-06-25) | 18.31% |
|---|---|
| 2 years (2020-06-25) | 35.72% |
| 3 years (2019-06-25) | 72.51% |
| 5 years (2017-06-23) | 39.41% |
Is Bristol-Myers Squibb Company under- or over-valued?
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's P/E ratio
Bristol-Myers Squibb Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Bristol-Myers Squibb Company shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Bristol-Myers Squibb Company's PEG ratio
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4369. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.1 billion.
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.
Bristol-Myers Squibb Company financials
| Revenue TTM | $47 billion |
|---|---|
| Operating margin TTM | 22.19% |
| Gross profit TTM | $37 billion |
| Return on assets TTM | 6.05% |
| Return on equity TTM | 18.08% |
| Profit margin | 13.31% |
| Book value | $14.83 |
| Market capitalisation | $168.1 billion |
TTM: trailing 12 months
Bristol-Myers Squibb Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bristol-Myers Squibb Company's total ESG risk score
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 01/01/2019) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bristol-Myers Squibb Company's environmental score
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's social score
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol-Myers Squibb Company's governance score
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Bristol-Myers Squibb Company share dividends
Dividend payout ratio: 27.33% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 27.33% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.93% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 2.93% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.06 per share.
While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 1 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 30 June 2022 (the "ex-dividend date").
Have Bristol-Myers Squibb Company's shares ever split?
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 7 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
Bristol-Myers Squibb Company share price volatility
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as $52.3712 up to $79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.4796. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
Bristol-Myers Squibb Company overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
Find the best investment newsletters in Canada
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…
Sectors and stocks that might protect you from rising interest rates
Here are some investment ideas that could do well despite rising interest rates.
Read more…
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…More guides on Finder
-
How to buy Acadian Timber stock in Canada
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
-
How to buy Mobilicom Limited (MOB) stock in Canada when it goes public
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
-
How to buy Consumer Staples Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
-
How to buy Schwab U.S. REIT ETF stock in Canada
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
-
How to buy iShares US Consumer Staples ETF stock in Canada
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
-
How to buy Vanguard Real Estate Index Fund ETF Shares stock in Canada
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
-
How to buy SPDR S&P Insurance ETF stock in Canada
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
-
How to buy Financial Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
-
How to buy Invesco Dynamic Energy Exploration-and-Production ETF stock in Canada
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
-
How to buy First Trust Natural Gas ETF stock in Canada
Steps to owning and managing FCG stock, with 24-hour and historical pricing before you buy.